Cancer Advisor

Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146  (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balstilimab in patients wit...

Abstract Background: Metastatic castration‑resistant prostate cancer (mCRPC) remains incurable despite modern multimodal therapy including androgen deprivation therapy (ADT) and PSMA‑targeted radioligand therapy. Repurposed antiparasitic agents such as ivermectin, mebendazole, and fenbendazole have attracted interest for potential anticancer effects based on preclinical mechanisms and anecdotal clinical reports. Additionally, an in silico simulated randomized trial has proposed a comprehensive multimodal integrative regimen combining repurposed drugs with diet, supplements, and conventional therapy. Methods: This narrative review synthesizes clinical evidence for standard therapies in advanced prostate cancer and evaluates the available preclinical literature on repurposed antiparasitics. It also integrates data from large case report compilations and in silico simulations to illustrate the current landscape and highlight critical limitations. Results: ADT and ^177Lu‑PSMA‑617 radiol...

Introduction: A New Era in Cancer Care Cancer treatment is evolving faster than ever. From cutting-edge immunotherapies to AI-driven diagnostics, the discoveries of 2025–2026 are reshaping how clinicians detect, monitor, and treat malignancies. These breakthroughs offer hope for longer survival, improved quality of life, and personalized therapies tailored to each patient. Credit:  Statista 1. Immunotherapy: Expanding Beyond Checkpoints Immune checkpoint inhibitors (like pembrolizumab and nivolumab) remain foundational, while CAR‑T therapies, bispecific antibodies, and tumor-infiltrating lymphocytes (TILs) expand treatment options for previously resistant solid tumors. Key Highlights: CAR‑T therapy demonstrates survival benefits in advanced gastric and gastroesophageal junction cancers — a first for solid tumors. Bispecific and dual checkpoint agents provide deeper, more durable responses in early trials. Note: These therapies carry potential risks, including cytokine release syn...

Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...

Introduction Facing a cancer diagnosis can feel like navigating an endless maze with no clear direction. The overwhelming emotions and confusion that accompany such news are shared by many. While conventional cancer treatments like chemotherapy and radiation therapy have a role to play, there’s a growing interest in alternative therapies that can complement or even replace traditional methods. Did you know that many alternative cancer treatments have been explored, offering new hope to those affected by cancer? The use of complementary and alternative medicine is becoming more prevalent as patients seek options beyond conventional medical treatments. Alternative medicine includes therapies used outside of standard medical practices, offering different approaches to treat cancer. Integrative medicine combines both conventional and alternative treatments, aiming to improve outcomes and enhance quality of life. Diverse cancer hallmarks targeted by repurposed non-oncology drugs. This figu...